Zudena 100 mg (Udenafil) 30 Tablets
- Brand: MedyPharma
- Product Code: ZUDE 001
- Reward Points: 119
- Availability: 2-3 Days
- Ex Tax: $119.00
- Price in reward points: 1190
Zudena 100 Mg (Udenafil)
Zudena 100 mg contains the active ingredient Udenafil – the latest PDE5 inhibitor (phosphodiesterase type 5 inhibitor) type of medication for erectile dysfunction (ED) treatment. Zudena (Udenafil) is the new approved ED drug.
Udenafil is a drug used in urology to treat erectile dysfunction. It belongs to a class of drugs called PDE5 inhibitor, which many other erectile dysfunction drugs such as avanafil, sildenafil, tadalafil, and vardenafil also belong to. It was developed by Dong-A Pharmaceutical and is marketed under the trade name Udzire. With a maximum blood plasma concentration reached after 1.0 to 1.5 hours and a half life of 11 to 13 hours (a relatively rapid onset and a long duration of action), both on-demand and once-daily use of udenafil have been reported. Typical doses are 100 and 200 mg. Udenafil is available in Korea, Russia, and Philippines; in the United States, it is not approved for use U.S. Food and Drug Administration.
Erectile dysfunction (ED) is an inability to achieve or sustain an erection suitablefor s**ual intercourse. S**ologists say at least 10% men in India may have to use these drugs at some point. Studies have shown that 40% of men up to the age of 40 years have ED andit goesup 70% by 60 years. The commonly prescribed drugs for the disorder in India are sildenafil(Viagra) and tadalafil,which belong to a category called phosphodiesterasetype5 drugs. Now, Zydus, a pharmaceutical company, has got exclusive permission to sell udenafil. It’s not always that the release of a drug is celebrated by many, particularly men. A drug that was released in India last week is the recent in the list of drugs that has a cure for erectile dysfunction. The manufacturers say udenafil, which will be marketed under the brand name Udezire, will be long-acting, but with minimal side effects.
Erectile dysfunction (ED) is an inability to achieve or sustain an erection suitable for s**ual intercourse. S**ologists say at least 10% men in India may have to use these drugs at some point. Studies have shown that 40% of men up to the age of 40 years have ED and it goes up 70% by 60 years Udenafil has a trade name Udzire. This is one of the four famous molecules investigated for the treatment of erectile dysfunction (ED). It is well-known with proven clinical efficiency, high safety and acceptability to the patient. The unique qualities of Udzire makes it perfect choice for the user.
Udzire provides quick and strong onset of action, which lasts to twenty-four hours. Udzire does not have testicular toxicity. Certainly, all of these properties will be the best in its segment.Udenafil comes in oval shaped tablets, film-coated light-pink color with light-yellow shade. There are imprinted symbol “100” on one side and symbols “Z” and “Y” on another
1 tablet contains 100 mg of udenafil;
There are one or four tablets per pack.
Udzire greatly improves erection and the possibility of successful s**ual intercourse. The action of the drug has an optimal duration – up to twenty-four hours. Effect appears after thirty minutes after taking the drug in the presence of s**ual arousal.
– Regulators potency
The composition and the form
Tablets, film-coated udenafil 100 mg, Adjuvants: lactose, maize starch, colloidal silicon dioxide; L-hydroxypropylcellulose, hydroxypropyl-LF; talc, magnesium stearate, Jacket: hydroxypropyl methylcellulose, talc, iron oxide red, iron oxide yellow, titanium dioxide, packages stripes 1, 2 or 4 pieces.; in a carton pack 1 (for 1 or 4 pcs.) or 2 (for 2 pcs.) packaging. Coated tablets light pink color with a tinge yellow, oval imprinted with the symbol “100” on one side and symbols in the form of letters «Z» and «Y», risk-sharing – on the other. At the break – a white or nearly white.
– Improves erectile function.
Treatment of erection disorders, characterized by the inability to achieve or maintain penile erection sufficient for satisfactory s**ual intercourse.
Oral udenafil is rapidly absorbed and produces effect in 30-90 minutes (on average – 60 minutes). Udenafil half-life is 12 hours, due to high binding to plasma proteins (93.9%) effective period extends up to 24 hours after receiving a single dose. Alcohol and food have no effect on the udenafil absorbability. Drinking alcohol at 112 ml (equivalent to 40% ethyl alcohol) in combination with oral udenafil a dose of 200 mg does not affect the pharmacokinetic profile of udenafil. Udenafil does not accumulate in the body, even continuous intake does not produce significant changes in its pharmacokinetics.
Udenafil is a selective reversible inhibitor of specific phosphodiesterase type 5-th (PDE-5), promotes metabolism of cyclic guanosine monophosphate (cGMP).
Udenafil no direct relaxing effect on isolated corpus cavernosum, but enhances s**ual stimulation relaxing effect of nitric oxide by inhibiting PDE-5, responsible for the breakdown of cGMP in the cavernous body. The result is relaxation of smooth muscles of arteries and blood flow to the tissues of the pe**is that causes erections. The drug has no effect in the absence of s**ual stimulation. Research in vitro shown that udenafil is a selective inhibitor of the enzyme PDE-5. PDE-5 is present in smooth muscles of the corpus cavernosum, vascular smooth muscle in internal organs, skeletal muscle, platelets, kidney, lung and cerebellum. Udenafil is 10000 times more potent inhibitor for PDE-5 than for PDE-1, PDE 2, PDE-3 and PDE-4, which are located in the heart, brain, blood vessels, liver and other organs. In addition, udenafil 700 times more active against PDE-5 than for PDE-6, found in the retina and responsible for color perception. Udenafil not inhibit PDE-11, hence the lack of cases of myalgia, back pain, and manifestations of testicular toxicity. Udenafil improves erection and the possibility of successful s**ual intercourse. The action of the drug lasts up to 24 h. The effect is manifested as early as 30 minutes after taking the drug in the presence of s**ual arousal. Udenafil in healthy individuals does not cause reliable changes in SBP and DBP compared with placebo in the position of “lying” and “standing up” (mean maximum decrease of 1,6 / 0,8 mmHg and 0,2 / 4,6 mm mmHg, respectively). Udenafil no effect on recognition of colors (blue / green), which explains its low affinity for PDE-6. Udenafil no effect on visual acuity, elektroretinogrammu, intraocular pressure and pupil size. In the study of udenafil men revealed no clinically significant effect on the drug quantity and concentration of sperm motility and morphology of spermatozoa. Prescribed medication Zidena®, Treatment of erection disorders, characterized by the inability to achieve or maintain penile erection sufficient for satisfactory s**ual intercourse.
Hypersensitivity to any component of the drug; simultaneous reception of nitrates and other donor of nitric oxide.
patients with uncontrolled arterial hypertension (blood pressure> 170/100 mm Hg. st), hypotension (BP <90/50 mm Hg. Art.) patients with hereditary degenerative diseases of the retina (including retinitis pigmentosa, proliferative diabetic retinopathy); patients who had undergone during the last 6 months of stroke, myocardial infarction, or aorto-coronary bypass surgery; Patients with severe hepatic or renal insufficiency; presence of a congenital syndrome of QT prolongation or increase of the QT interval as a result of taking the drugs; predisposition to priapism; patients with anatomical deformation of the pe**is; presence of penile implant; during s**ual activity in patients with cardio-vascular system, as unstable angina or angina occurring during s**ual intercourse, chronic heart failure (II-IV functional class according to the classification NYHA), evolved in the past 6 months, uncontrolled cardiac arrhythmia – should take into account the potential risk for complications; while receiving of udenafil and CCBs, alpha-blockers or other hypotensive drugs – may mark the additional reduction in SBP and DBP by 7-8 mmHg
The product is not intended for use in children and adolescents under the age of 18 years.
Application of pregnancy and breastfeeding
According to the registered indication the drug is not intended for use in women.
Side effects of Udenafil
Palpitations, prolonged erections, flushing, dizziness eye pain, increased lacrimation, nasal congestion, headache. There is no research for its side effects for the men over 71 y.o. There are no side effects on sperm quality.
Inhibitors of cytochrome P450 isoenzyme CYP3A4 (ketoconazole, itraconazole, ritonavir, indinavir, cimetidine, erythromycin, grapefruit juice) may enhance the action of udenafil. Ketoconazole (400 mg) increases the bioavailability and Cmax of udenafil (100 mg) almost 2-fold (212%) and 0.8-fold (85%), respectively. Ritonavir and indinavir substantially increases the effects of udenafil. Dexamethasone, rifampin, and anticonvulsants drugs (carbamazepine, phenytoin and phenobarbital) may accelerate the metabolism of udenafil, so joint application with the above medications weakens the effect of udenafil. The joint application of udenafil (30 mg / kg orally) and nitroglycerin (2.5 mg / kg once, w / w) did not reveal any effect on the pharmacokinetics of udenafil in experimental studies, but the simultaneous use of nitroglycerin and of udenafil is not recommended because of possible reduce blood pressure. Udenafil and drugs from the group of alpha-blockers are vasodilator, therefore, in the joint admission should be appointed at the minimum doses.
Symptoms: with single dose of the drug in a dose of 400 mg of adverse events were comparable to those observed when receiving of udenafil at lower doses, but occurred more frequently. Treatment: symptomatic. Dialysis does not accelerate the elimination of udenafil.
Dosing and Administration
Inside, regardless of the meal. Recommended dose- 100 mg, taken 30 minutes before anticipated s**ual activity. The dose may be increased to 200 mg given individual efficacy and tolerability. The maximum recommended frequency of application – 1 times per day.